Ennismore Fund Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Ennismore Fund Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$2.13M	Buy	+4,501	New	+$2.19M	2.97%	17

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ennismore Fund Management's REGN Position: Q1 2021 in Review

Ennismore Fund Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2021: 4,501 shares worth $2.13M. The stake represents 2.97% of the portfolio and ranks #17 among its holdings.

924 funds tracked by Wall St. Rank hold REGN as of Q1 2021.

Ennismore Fund Management held 4,501 shares of Regeneron Pharmaceuticals worth $2.13M as of Q1 2021.
Regeneron Pharmaceuticals was a new Ennismore Fund Management position in Q1 2021.
Regeneron Pharmaceuticals made up 2.97% of Ennismore Fund Management's portfolio in Q1 2021, its #17 holding.
924 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2021.

Based on Ennismore Fund Management's 13F filing for Q1 2021, filed 30 Apr 2021.